Table 3.
One year mortality risk after TE diagnosis by Cox proportional hazard*
| MortalityHazard ratio | 95% CI | P | |
|---|---|---|---|
| Female | 1.00 | 0.68–1.51 | 0.964 |
| Age at study entry | 1.01 | 0.99–1.03 | 0.279 |
| IDU antecedent | 1.09 | 0.75–1.56 | 0.654 |
| Time from AIDS to TE | 1.30 | 1.03–1.64 | 0.028 |
| TE prophylaxis | 0.91 | 0.94–1.30 | 0.613 |
| PJP | 1.21 | 0.74–2.09 | 0.417 |
| Recurrent pneumonia | 2.53 | 1.17–5.47 | 0.018 |
| Wasting syndrome | 2.17 | 1.35–3.48 | < 0.01 |
| Kaposi sarcoma | 2.14 | 0.90–5.08 | 0.084 |
| CD4 + T cell ³ 200/μL | 0.62 | 0.35–1.09 | 0.101 |
| HAART | 0.48 | 0.17–0.88 | 0.017 |
*
TE = toxoplasmic encephalitis; CI = confidence interval; IDU = injecting drug use; AIDS = acquired immunodeficiency syndrome; PJP = Pneumocystic jirovecii pneumonia; HAART = highly active antiretroviral therapy.